**LETTER TO JMG**

Mitochondrial DNA haplogroups influence the Friedreich’s ataxia phenotype

M Giacchetti, A Monticelli, I De Biase, L Pianese, M Turano, A Filla, G De Michele, S Cocozza

---

**Friedreich’s ataxia**, an autosomal recessive neurodegenerative disorder, is the most common hereditary ataxia among white people. The disease is characterised by gait and limb ataxia, dysarthria, absent tendon reflexes, Babinski’s sign, impairment of position and vibratory senses, scoliosis, and pes cavus. Cardiac manifestations are prominent in some cases. Diabetes mellitus or carbohydrate intolerance is frequently described. The age of onset is variable. The disease usually comes at puberty but several cases have become symptomatic after 40 years. The molecular defect that occurs in Friedreich’s ataxia is the trinucleotide GAA expansion in the first intron of the X25 gene. This gene encodes for a 210 aa mitochondrial protein called frataxin. Levels of frataxin mRNA and protein are severely reduced as a result of this expansion. Although the exact physiological function of frataxin is not known, its involvement in iron–sulphur (Fe–S) cluster biogenesis has been suggested.

The Friedreich’s ataxia phenotype shows a variable expression with respect to the age of onset and the presence of some signs or symptoms. Disease duration has been proposed to influence dysarthria, decreased vibration sense, optic atrophy, and diabetes. Some Friedreich’s ataxia phenotype features are strongly correlated with GAA expansion size. An inverse relationship has been demonstrated between GAA repeat size and the age of onset. Friedreich’s ataxia with retained reflexes or absence of cardiomyopathy was associated with shorter expansions. In a previous report, we demonstrated that GAA size accounts for about 70% of the onset age variance, with sibling age of onset independently accounting for an additional 13%. Then we suggested that siblings shared genetic or environmental factors that, in addition to the GAA size, influence the age of onset. Modifier genes are defined on the basis of their ability to modulate the clinical phenotype of individuals with monogenic and multigenic diseases. Mitochondrial DNA (mtDNA) could be considered a candidate modifier factor for neurodegenerative disorders, since mitochondrial oxidative stress is thought to be involved in the pathogenesis of these diseases. MtDNA is maternally inherited and highly polymorphic. Population specific mtDNA polymorphisms create groups of related mtDNA haplotypes, or haplogroups. The majority of the European mtDNAs can be classified within nine mtDNA haplogroups, designated as H, I, J, K, T, U, V, W, and X. Several haplogroups have been associated with polymorphic biological features in healthy individuals. In particular, haplogroup J has been associated with increased longevity in Europeans and reduced efficiency of ATP production during oxidative phosphorylation. Moreover, the T haplogroup has been associated with reduced spermatozoa motility. MtDNA haplogroups can also play an important role in modulating disease expression. Extensive analysis of the mtDNAs of patients with Leber hereditary optic neuropathy has revealed that certain mtDNA haplogroups are prone to expression of the disease more than others.

Individuals classified as haplogroups J or K demonstrate a significant decrease in risk of Parkinson’s disease, as against individuals carrying the most common haplogroup H. In addition, tRNA_\text{gln} nucleotide position 4336 variant in individuals belonging to the haplogroup H is associated with late onset Alzheimer’s disease.

**SUBJECTS AND METHODS**

**Sample and DNA extraction**

A total of 99 patients with Friedreich’s ataxia (54 men and 45 women), with known GAA expansion sizes, and 48 control individuals, all from southern Italy, were included in the present study. All of them were informed on the aims of the study and gave their informed consents to the genetic study and gave their informed consents to the genetic analysis. Genomic DNA was isolated from blood nucleated cells (2 ml of peripheral blood) according to standard techniques. Because of the maternal inheritance of mtDNA, only unrelated patients were selected for the study.

**Polymerase chain reactions and electrophoresis**

The GAA triplet repeat sizes were typed by polymerase chain reaction (PCR). Primers for the PCR were designed and numbered according to GenBank sequence accession numbers U43748. PCR was performed as previously described. The smaller and the larger in each pair of GAA alleles were indicated as GAA1 and GAA2, respectively.

**MtDNA haplogroup analysis**

Haplogroup typing has been carried out by restriction analyses of mtDNA according to De Benedictis et al. For each individual, mtDNA was amplified with the appropriate

---

**Key points**

- Friedreich’s ataxia, the most common hereditary ataxia among white people, is caused by a trinucleotide GAA expansion in the X25 gene.
- Friedreich’s ataxia is characterised by a variable phenotype which may also include hypertrophic cardiomyopathy and diabetes.
- We report an influence of the mitochondrial DNA (mtDNA) haplogroups on the Friedreich’s ataxia phenotype.
- Patients belonging to the U mtDNA haplogroup class were found to have a delay of 5 years in the disease onset and a lower rate of cardiomyopathy.

**Abbreviations:** ANCOVA, analysis of covariance; PCR, polymerase chain reaction
The GAA expansion size is strongly related to the age of onset, accounting for about 70% of variance. To explore the influence of other genetic factors, which modify the age of onset in addition to the GAA size, we investigated the possible role of mtDNA haplogroups on the Friedreich’s ataxia clinical manifestations. We classified our subjects into the nine European mtDNA haplogroups: H, I, J, K, T, U, V, W, and X. We were able to include 128 individuals (87.1%)—84 patients and 44 controls—in defined haplogroups. The mean age of onset of Friedreich’s ataxia in our patients was 15.8 (standard deviation, 8.52) years, mean GAA1 length was 654 (238) repeats and mean GAA2 length was 869 (191) repeats. No significant difference was found in the frequency distribution of mtDNA haplogroups between patients with Friedreich’s ataxia and healthy controls ($\chi^2 = 8.35$, p=0.05), see table 1.

To test the hypothesis that mtDNA haplogroups could influence the age of onset, we performed a multiple regression analysis. The haplogroup independent variable was coded as 0 = absence and 1 = presence. A stepwise multiple regression of age at onset on GAA1 size, GAA2 size and mtDNA haplogroups showed that only GAA1 size and haplogroup U contributed significantly to the regression (see table 2). In particular we observed that haplogroup U seems to have a protective effect, delaying the age of onset for an average of approximately 5 years. Haplogroups H, J, K, and T did not influence the regression significantly. In addition, to control the effect of GAA1, an analysis of covariance (ANCOVA) was performed (independent variable: presence of U; dependent variable: age at onset; covariate: GAA1). ANCOVA confirmed the effect of U haplogroup on onset age ($F = 12.79$; p<0.001), see figure 1.

As previously stated, variations in disease presentation concern not only the age of onset, but also the presence of several clinical features, such as diabetes and cardiomyopathy. Diabetes mellitus is present in about 14% of Friedreich’s ataxia patients and it develops, usually, in a late stage of the disease, after a mean disease duration of 15 years.

**Cardiac involvement in Friedreich’s ataxia** is well studied and is characterised by an increased thickness of the ventricular wall, a normal or small left ventricular cavity, and, usually, a normal systolic function. Occurrence of cardiomyopathy appears to be constant at pathological examination, very frequent at echocardiography, and less common when echocardiography is used. We investigated the possible influence of haplogroups on the development of diabetes mellitus and cardiomyopathy in our population sample. We found no significant relationship between haplogroups and diabetes (data not shown). This finding is not unexpected since diabetes has been demonstrated to be associated more with disease duration than with genetic factors. On the other hand, the presence of cardiomyopathy has been demonstrated to be influenced by GAA1 repeat size. To take this influence into account, we divided our patients into two subgroups according to their GAA1 repeat size. The first group (A) included patients with shorter GAA repeats (less than the mean value of GAA1 size of the population), while the second group (B) included patients with larger expansions (more than the mean value of GAA1 size of the population). The mean value of GAA1 in our population, 654 triplets, is also consistent with the threshold above which frataxin expression is too low to influence the clinical presentation. Table 3 shows the frequencies of haplogroups H, J, K, T, and U in patients with Friedreich’s ataxia, classified according to the presence or absence of hypertrophic cardiomyopathy, as shown by echocardiographic examination, and to the repeat length. Less frequent haplogroups V, X, W, and I were excluded from the analysis. While in the majority of patients with H and J haplogroups, the presence of hypertrophic cardiomyopathy is strongly influenced by repeat size, in patients belonging to haplogroups K, T, and U other genetic factors modify the age of onset, which is not strongly related to GAA1 repeat length.
the U and T haplogroups, hypertrophic cardiomyopathy is generally less frequent and independent on the GAA size. Analysing our samples using a Fisher 2 by 5 test, a significant difference in cardiomyopathy frequency \( (p<0.05) \) has been found for patient group A.

In summary, haplogroup U seems also to have a protective effect on the development of the cardiomyopathy in Friedreich’s ataxia. Haplogroup U has already been correlated to certain human diseases. Previous reports showed its involvement in the migrainous stroke in the Finnish population. \(^{19}\) A protective role of haplogroup U has been suggested in Alzheimer’s disease. In Alzheimer’s disease, apolipoprotein E \( e_4 \) allele polymorphism has been demonstrated to represent a susceptibility factor. Carrièr et al found that haplogroups U and K seem to neutralise the harmful effect on the development of the cardiomyopathy in Friedreich’s ataxia. \(^{20}\) A protective role of haplogroup U has been suggested to confirm this data.

In this study, we report an influence of haplogroup U on the Friedreich’s ataxia phenotype. Patients belonging to this mtDNA class seem to have a delay in the disease onset and a lower rate of cardiomyopathy. Other populations with different backgrounds should be examined to confirm this data.

ACKNOWLEDGEMENTS

We wish to thank Dr Giovanni Coppola for the statistical analysis support.

Authors’ affiliations

M Giachetti, A Monticelli, I De Biasi, L Pianese, M Turano, S Coccoza, Dipartimento di Biologia e Patologia Cellulare e Molecolare “L. Calafato” Università “Federico II”, Via S Pansini, 5, 80131 Napoli, Italy
A Monticelli, IEGS CNR
L Pianese, M Turano, BioGenM Consortium
A Filla, G De Michele, Dipartimento di Scienze Neurologiche, Università Federico II, Via S Pansini, 5, 80131 Napoli, Italy

Correspondence to: Prof S Coccoza, Dipartimento di Biologia e Patologia Cellulare e Molecolare “L. Calafato” Università “Federico II”, Via S Pansini, 5, 80131 Napoli, Italy; coccoza@unina.it

Received 10 October 2003
Accepted for publication 22 December 2003

Table 3  Frequencies of haplogroups H, J, K, T, and U in patients with Friedreich’s ataxia, classified according the presence or absence of hypertrophic cardiomyopathy (HCM) and the repeat length

<table>
<thead>
<tr>
<th>Haplogroups</th>
<th>Group A</th>
<th>Group B</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HCM+</td>
<td>HCM-</td>
</tr>
<tr>
<td>H</td>
<td>16</td>
<td>4</td>
</tr>
<tr>
<td>J</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td>K</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>T</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>U</td>
<td>2</td>
<td>5</td>
</tr>
</tbody>
</table>

Group A includes patients carrying a GAA expansion <654 triplets. Group B includes patients carrying a GAA expansion ≥654 triplets. HCM+/− means the presence or absence of hypertrophic cardiomyopathy.

REFERENCES